The story of Viagra presents a interesting case for observers in the pharmaceutical sector. While initially a phenomenal success, generating huge profits, the patent end and the subsequent arrival of generic competitors have significantly changed income. This presents questions about the ongoing viability of similar therapeutic projects and suggest